✦ LIBER ✦

Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD)

✍ Scribed by Bladé, Joan; Miguel, Jesús San; Sanz-Sanz, Miguel Angel; Alcalá, Antonio; Hernández, JoséM.; Martínez, Miguel; García-Conde, Javier; Moro, Jesús; Ortega, Fernando; Fontanillas, Montserrat

Book ID: 123302096
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 540 KB
Volume: 29
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(93)90576-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of alkylating resistant multip

Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP)

✍ Bladé, Joan; Rozman, Ciril; Montserrat, Emili; Cervantes, Francisco; Feliu, Evar 📂 Article 📅 1986 🏛 Elsevier Science ⚖ 487 KB

Post-transplant outcomes of induction th

Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support

✍ Dan T. Vogl; Stephen V. Liu; Elise A. Chong; Selina M. Luger; David L. Porter; S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

TREATMENT OF PLASMA CELL LEUKAEMIA AND R

TREATMENT OF PLASMA CELL LEUKAEMIA AND RESISTANT/RELAPSED MULTIPLE MYELOMA WITH VINCRISTINE, MITOXANTRONE AND DEXAMETHASONE (VMD PROTOCOL)

✍ Pellegrino Musto; Michele Mario Greco; Antonietta Falcone; Mario Carotenuto 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Comparison of oral melphalan, CCNU, and

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience

✍ Gibbons G. Cornwell III; Thomas F. Pajak; Shaul Kochwa; O. Ross McIntyre; Linda 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 586 KB

Short and long-term outcome of treatment

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis

✍ Saulius Girnius; David C. Seldin; Martha Skinner; Kathleen T. Finn; Karen Quille 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 142 KB